Trial Profile

An Open Phase I Study to Evaluate the Safety, Tolerability, PK / PD, and Initial Efficacy of HBM4003 in Combination With Toripalimab in Patients With Advanced Melanoma and Other Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Porustobart (Primary) ; Toripalimab (Primary)
Indications Carcinoma; Malignant melanoma; Renal cell carcinoma; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Harbour BioMed

Most Recent Events

28 Aug 2023 Results presented in a Harbour BioMed media release.
08 Dec 2022 According to a Harbour BioMed media release, as of 31 August 2022, a total of 40 patients had been dosed.
08 Dec 2022 Results presented in a Harbour BioMed Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com